Chugai to develop cancer inhibitor; Enzon replaces CEO with executive committee;

 @FierceBiotech: Basilea suffers setback as EU won't back its lead drug ceftobiprole. Article  | Follow @FierceBiotech

 @JohnCFierce: Shire plans to undercut Cerezyme by 15% on price. Could a price war be shaping up? That's $30K less per patient. Article | Follow @JohnCFierce 

> Cancer-focused biotech Curis reports that its Japanese partner Chugai Pharmaceutical plans to develop GDC-0449, a Hedgehog pathway inhibitor that fights cancer. Report

> Enzon Pharmaceuticals today announced that Jeffrey Buchalter has resigned as the company's CEO and director, effective immediately, and has been replaced by a newly formed executive committee of the board. Release

> Albert Halluin, a noted biotech patent attorney and senior counsel at Wilson Sonsini Goodrich & Rosati, died Friday after his single-engine plane crashed in California. Halluin was 70 years old. Story

> Israel's NasVax said on Sunday it had signed an agreement with Novartis to jointly investigate the feasibility of developing vaccines using its VaxiSome technology, including an improved flu vaccine. Article

> The U.K. government is committed to maintaining a "very competitive" tax regime for businesses, U.K. Business Secretary Peter Mandelson said Monday, as the government hosted an investment conference for global executives in London. Story

> Cubist Pharmaceuticals has appointed of Leon (Lonnie) Moulder Jr. to its board of directors. Most recently, Moulder served as VP, president and CEO of Abraxis BioScience from April 2009 to January 2010. Release

And Finally... Dolphins can actually "turn on" diabetes and turn it off again depending upon whether there's a lot of food available to them or very little, according to new research.  Story